close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Innate Pharma S.A. - American Depositary Shares (NQ:IPHA)

1.790 -0.020 (-1.10%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Innate Pharma S.A. - American Depositary Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Innate Pharma to Participate in Upcoming Investor Conference
From Innate Pharma SA
Via Business Wire
News headline image
Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis ↗
Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the... 
Via Benzinga
News headline image
Number of Shares and Voting Rights of Innate Pharma as of April 1, 2023
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 12, 2023
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Files Its 2022 Universal Registration Document (Document d’enregistrement universel) and 2022 Annual Report on Form 20-F
From Innate Pharma SA
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Innate Pharma Announces Exclusive License of Antibodies to Takeda for Celiac Disease Research Program
From Innate Pharma SA
Via Business Wire
News headline image
Earnings Scheduled For March 23, 2023 ↗
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter. 
Via Benzinga
News headline image
Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update
From Innate Pharma SA
Via Business Wire
News headline image
Number of Shares and Voting Rights of Innate Pharma as of March 1, 2023
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Conference Call and Webcast for Full Year 2022 Financial Results
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Provides Update on Silicon Valley Bank Exposure
From Innate Pharma SA
Via Business Wire
News headline image
Number of Shares and Voting Rights of Innate Pharma as of February 1, 2023
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma to Participate in Upcoming Investor Conferences
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Engagers
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology
From Innate Pharma SA
Via Business Wire
News headline image
US Stocks Open Lower; Nasdaq Slides Over 100 Points ↗
U.S. stocks traded lower this morning, with the Nasdaq Composite dropping more than 100 points on Tuesday. 
Via Benzinga
News headline image
Why Shares of Chinese Companies Are Trading Higher? Here Are 55 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Elys Game Technology, Corp. (NASDAQ: ELYS) shares jumped 147% to $0.4312. Elys Game Technology and Cloakbook DC have been granted license to open sportsbook in Washington, D.C. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial. 
Via Benzinga
News headline image
After Five Years Of Collaboration, Sanofi & Innate Pharma Expand Oncology Pact With Additional Programs ↗
 
Via Benzinga
News headline image
Why Innate Pharma Shares Are Trading Higher By 24%; Here Are 34 Stocks Moving Premarket ↗
Gainers AIM ImmunoTech Inc. (NYSE: AIM) shares rose 82.4% to $0.62 in pre-market trading. AIM ImmunoTech recently reported safety, tolerability and biological activity data for intranasal ampligen in... 
Via Benzinga
News headline image
Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Highlights Early Lacutamab Data In Aggressive Form Of Blood Cancer ↗
 
Via Benzinga
News headline image
Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022
From Innate Pharma SA
Via Business Wire
News headline image
Number of Shares and Voting Rights of Innate Pharma as of December 1, 2022
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma to present adenosine franchise, IPH5201 and IPH5301 at ESMO IO 2022
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Reports Third Quarter Financial Results
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2022 Business Update
From Innate Pharma SA
Via Business Wire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today